Correction: Inhibitor SBFI26 suppresses the malignant progression of castration-resistant PC3-M cells by competitively binding to oncogenic FABP5

Waseem Al-Jameel; Xiaojun Gou; Shiva S. Forootan; Majed Saad Al Fayi; Philip S. Rudland; Farzad S. Forootan; Jiacheng Zhang; Philip A. Cornford; Syed A. Hussain; Youqiang Ke

doi:10.18632/oncotarget.27690

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Inhibitor SBFI26 suppresses the malignant progression of castration-resistant PC3-M cells by competitively binding to oncogenic FABP5

PDF | How to cite

Oncotarget. 2020; 11:3025-3025. https://doi.org/10.18632/oncotarget.27690

Metrics: PDF 1412 views | ?

Waseem Al-Jameel¹, Xiaojun Gou², Shiva S. Forootan¹, Majed Saad Al Fayi¹, Philip S. Rudland³, Farzad S. Forootan¹, Jiacheng Zhang¹, Philip A. Cornford¹, Syed A. Hussain¹ and Youqiang Ke¹

¹ Molecular Pathology Laboratory, Department of Molecular and Clinical Cancer Medicine, Liverpool University, Liverpool, L3 9TA, United Kingdom
² Sichuan Antibiotics Industrial Institute, Chengdu University, Chengdu 610081, China
³ Department of Biochemistry, Liverpool University, Liverpool, L69 3GA, United Kingdom

Published: August 04, 2020

This article has been corrected: The following references were accidentally omitted from the published list:

54. Xu M, Joo HJ, Paik YK. Novel functions of lipid-binding protein 5 in Caenorhabditis elegans fat metabolism. J Biol Chem. 2011; 286:28111–8. https://doi.org/10.1074/jbc.M111.227165. [PubMed]

55. Pavese J, Ogden IM, Bergan RC. An orthotopic murine model of human prostate cancer metastasis. J Vis Exp. 2013; e50873. https://doi.org/10.3791/50873. [PubMed]

56. Janik P, Briand P, Hartmann NR. The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors. Cancer Res. 1975; 35:3698–704. [PubMed]

57. Thumser AE, Storch J. Characterization of a BODIPY-labeled fluorescent fatty acid analogue. Binding to fatty acid-binding proteins, intracellular localization, and metabolism. Mol Cell Biochem. 2007; 299:67–73. https://doi.org/10.1007/s11010-005-9041-2. [PubMed]

Original article: Oncotarget. 2017; 8:31041–31056. DOI: https://doi.org/10.18632/oncotarget.16055.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27690

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: Inhibitor SBFI26 suppresses the malignant progression of castration-resistant PC3-M cells by competitively binding to oncogenic FABP5